Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-spasticity agents for multiple sclerosis.

D T Shakespeare1, M Boggild, C Young

  • 1The Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley - Liverpool, UK, L9 7LJ. dts@fnmail.com

The Cochrane Database of Systematic Reviews
|November 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probing lepton flavour violation via neutrinoless [Formula: see text] decays with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

A new method to distinguish hadronically decaying boosted <i>Z</i> bosons from <i>W</i> bosons using the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Search for supersymmetry at [Formula: see text] TeV in final states with jets and two same-sign leptons or three leptons with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Measurement of the differential cross-sections of prompt and non-prompt production of [Formula: see text] and [Formula: see text] in <i>pp</i> collisions at [Formula: see text] and 8 TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Measurement of the transverse momentum and [Formula: see text] distributions of Drell-Yan lepton pairs in proton-proton collisions at [Formula: see text] TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Muon reconstruction performance of the ATLAS detector in proton-proton collision data at [Formula: see text]=13 TeV.

The European physical journal. C, Particles and fields·2017
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

The efficacy of anti-spasticity agents for multiple sclerosis (MS) is poorly documented. More research is needed to understand treatment rationale and develop sensitive measures for spasticity.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Spasticity is a prevalent and debilitating symptom in multiple sclerosis (MS) patients.
  • It significantly impacts quality of life, causing pain, spasms, functional loss, and caregiving challenges.
  • Current treatment options include various oral and parenteral medications.

Purpose of the Study:

  • To evaluate the absolute and comparative effectiveness and tolerability of anti-spasticity medications in individuals with MS.
  • To synthesize evidence from randomized controlled trials (RCTs) to inform clinical practice.

Main Methods:

  • A systematic search of multiple databases (MEDLINE, EMBASE) and other sources identified relevant double-blind, randomized controlled trials (RCTs) of at least seven days duration.
  • Data extraction was performed by two independent reviewers, with efforts to obtain missing data from principal investigators.

Related Experiment Videos

  • A meta-analysis was precluded by outcome measure inadequacy and study methodological limitations.

    • Main Results:

    • Twenty-three placebo-controlled and thirteen comparative studies met inclusion criteria, involving agents like baclofen, dantrolene, and tizanidine.
    • Few studies utilized validated scales like the Ashworth scale, with limited statistically significant differences reported between treatments.
    • Functional assessments yielded inconclusive results, and other symptom evaluations used unvalidated scores.

    Conclusions:

    • The current evidence base for the efficacy and tolerability of anti-spasticity agents in MS is insufficient for prescribing guidance.
    • Further research is required to elucidate the underlying mechanisms of upper motor neuron syndrome and develop robust, validated measures for spasticity assessment.